Takeda to strategically cut R&D after $62B Shire buy: Reuters by Amirah Al Idrus Thursday, May 17, 2018 Takeda's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don't deliver.
Chutes and Ladders—Achillion appoints Joseph Truitt CEO by Conor Hale Friday, May 4, 2018 Achillion appoints Joseph Truitt after CEO steps down; Lilly hires Leena Gandhi to lead new I-O team; and C4 promotes Andrew Phillips to CEO.
Crescendo raises $70M to trial bispecific T-cell engager by Nick Paul Taylor Monday, April 30, 2018 The financing equips Crescendo to show whether its vision for dialing up T-cell activity in the tumor microenvironment translates into humans.
Shire-hunting Takeda notches R&D collab with Nektar by Ben Adams Tuesday, April 24, 2018 Takeda has paired with Nektar to work on a new immuno-oncology combination trial.
Chutes & Ladders—Andrew Witty shifts to PBM as Optum's CEO by Angus Liu Friday, March 16, 2018 Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.
Time’s a-ticking for bankrupt Orexigen to sell off Contrave by Amirah Al Idrus Monday, March 12, 2018 Orexigen Therapeutics is filing for bankruptcy and will auction off its obesity drug to pay off debt.
Deal-hungry Takeda forges another R&D alliance by Phil Taylor Thursday, February 22, 2018 Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming with two Seattle-based academic centers.
Ipsen joins Arix’s growing pool of pharma partners by Nick Paul Taylor Wednesday, February 21, 2018 The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.
Takeda rides the neuro R&D Wave with latest biotech pact by Ben Adams Tuesday, February 20, 2018 Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.
BTI files for $69M IPO to run trials in Alzheimer's and cancer by Nick Paul Taylor Tuesday, February 13, 2018 BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
